GI Pancreatic - Metastatic

Localized

NeoAdjuvant

Adjuvant

IRB# 17751 Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

IRB# 15588 New study will be available soon.

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

Metastatic

IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

IRB# 19620 A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

IRB# 20408 New study will be available soon.

CROSS-DISEASE TRIALS:

IRB# TBD EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold

IRB #19211 A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

IRB#15588 New study will be available soon.

IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

IRB# 19620 A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

IRB# 20408 New study will be available soon.

CROSS-DISEASE TRIALS:

IRB# TBD EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment
In Development
Enrollment on Hold